Clinical Trial Update: A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of Brentuximab Vedotin in relapsed or refractory non-Hodgkin lymphoma has completed and results have been posted. The study evaluated patients w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma
• T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse | Phase 2 | Status: COMPLETED | Results posted: 2016-10-13